Projects / Programmes source: ARIS

New biomedical applications of electroporation

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B520  Biomedical sciences  General pathology, pathological anatomy 
B200  Biomedical sciences  Cytology, oncology, cancerology 
electroporation, electrochemotherapy, electrogenetherapy, tumors malignant, patients, tumors experimental
Evaluation (rules)
source: COBISS
Researchers (13)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  15973  PhD Božidar Casar  Physics  Researcher  2002 - 2004  126 
2.  14575  PhD Maja Čemažar  Oncology  Researcher  2002 - 2004  1,427 
3.  12179  PhD Tanja Čufer  Oncology  Researcher  2002 - 2004  774 
4.  21329  PhD Alenka Grošel  Oncology  Researcher  2002 - 2004  77 
5.  03282  Franc Guna  Oncology  Researcher  2002 - 2004  16 
6.  08801  MSc Maksimiljan Kadivec  Oncology  Researcher  2002 - 2004  131 
7.  16229  PhD Viljem Kovač  Medical sciences  Researcher  2002 - 2004  297 
8.  19058  PhD Simona Kranjc Brezar  Medical sciences  Researcher  2002 - 2004  315 
9.  04402  Franci-Stanko Marolt  Oncology  Researcher  2002 - 2004  43 
10.  12229  Gorazd Noč  Mathematics  Researcher  2002 - 2004 
11.  08007  PhD Srdjan Novaković  Oncology  Researcher  2002 - 2004  496 
12.  08750  PhD Zvonimir Rudolf  Oncology  Researcher  2002 - 2004  258 
13.  08800  PhD Gregor Serša  Oncology  Head  2002 - 2004  1,511 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,468 
Electroporation is a physical method that induces increased permeability of the cell membrane. Application of short intense DC electric pulses destabilizes the cell membrane, which enables faciliteted delivery of varios molecules, that have hampered transport through the cell membrane. Electroporation has proved to be effective for delivery of drugs, monoclonal antibodies and DNA. Lately, electroporation was used also for in vivo delivery of chemotherapeutic drugs and DNA into the tumors. The first approach was termed electrochemotherapy, the second electrogenetherapy. Our research group has been extensively involved in this research field for several years. Electrochemotherapy with cisplatin and bleomycin has proved to be effective in controling tumor growth locally in experimenatl tumor models in mice, as well as in treatment of various tumors in patients. Therefore, in this researh proposal it is foreseen to continue with the clinical study of electrochemotherapy with cisplatin or bleomycin on recurrent tumors of malignant melanoma, breast cancer, head and neck tumors and basal cell carcinoma of the skin. Besides cytotoxic effect, cisplatin and bleomycin have also radiosenzibilizing effect. In this project we will test electroporation as drug delivery for cisplatin and bleomycin in order to potentiate the radiation response of the experimental tumors in mice. Besides certain chemotherapeutic drugs, transfection of tumor cells with certain genes can facilitate the radioresponse of the tumors. Therefore we will test electroporation for p53 gene transfection, optimize the procedure, and determine antitumor effectivenss in combination with ionizing radiation. The concept of the project is to further develop electrochemotherapy in treatment of malignant tumors in humans, as well as to introduce electroporation into the radiation oncology as an method for delivery of radiosensitizing drugs or radiosensitizing genes.
Views history